Investor relations. Dorian Hare Senior Vice President, Investor Relations T: 650-590-4323 dorian.hare@oportun.com. Transfer agent. Equiniti P.O. Box 64854. St ...
We are committed to developing treatments for patients with devastating ophthalmic diseases and to maximizing value for our shareholders.” Initial, top-line ...
Investor Relations. Investors. Investors. Overview ... Ocuphire Pharma is a clinical-stage ophthalmic ... Ocuphire Pharma, Inc. 37000 Grand River Ave., Suite 120
Investor Relations · Investor Relations · Board & Management · Corporate Governance · Stock Information · Event Calendar · News Releases · SEC Filings ...
Missing: opht | Show results with:opht
The Investor Relations website contains information about National Vision Holdings, Inc.'s business for stockholders, potential investors, and financial ...
Missing: opht | Show results with:opht
Ocular Therapeutix is a biopharmaceutical company developing transformational treatments that enhance people's vision and quality of life through consistent ...
The Investor Relations website contains information about IRIDEX's business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about RxSight's business for stockholders, potential investors, and financial analysts.
Missing: opht | Show results with:opht
People also ask
How much can you make in investor relations?
Who funds Oportun?
What is the mission of Oportun?
What is the role of an investor relations officer?
The Investor Relations website contains information about Outlook Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts ...
OPHT-G. Contacts: Investors. Kathy Galante. Ophthotech Corporation. Vice President, Investor Relations and Corporate Communications. 212-845-8231. kathy.galante ...